SeekingAlpha · Sep 7, 2026
NASDAQ · HCM
HUTCHMED (China) Limited American Depositary Shares
Healthcare · Drug Manufacturers - Specialty & Generic
$14.09
Down-$0.21 (-1.49%)
Updated Sep 9, 2026, 1:05 AM
SID Score
7.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.39B
- P/E ratio
- 5.13
- Dividend yield
- 0.00%
- 52-week range
- $9.77 – $18.30
- Volume
- 150.5K
- Avg. volume
- 38.74K
Price performance
HCM price history
1M range · 19 trading sessions · Daily adjusted prices
HCM closed at $14.09 after 19 trading sessions, up 12.99% for the selected period.
- Last close
- $14.09
- Period change
- +12.99%
- Period low
- $11.91
- Period high
- $14.11
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $14.25 | $14.325 | $14.065 | $14.09 | 150.5K |
| Sep 3, 2026 | $13.60 | $14.23 | $13.51 | $14.11 | 511.72K |
| Sep 2, 2026 | $11.95 | $12.15 | $11.95 | $12.04 | 62.31K |
| Sep 1, 2026 | $12.14 | $12.14 | $11.80 | $11.91 | 74.51K |
| Aug 31, 2026 | $12.44 | $12.44 | $12.08 | $12.12 | 76.28K |
| Aug 28, 2026 | $12.40 | $12.48 | $12.34 | $12.38 | 59.14K |
| Aug 27, 2026 | $12.31 | $12.45 | $12.31 | $12.415 | 91.43K |
| Aug 26, 2026 | $12.41 | $12.56 | $12.34 | $12.35 | 62.75K |
| Aug 25, 2026 | $12.18 | $12.30 | $12.16 | $12.26 | 73.56K |
| Aug 24, 2026 | $12.58 | $12.58 | $12.09 | $12.18 | 56.36K |
| Aug 21, 2026 | $12.56 | $12.70 | $12.545 | $12.63 | 64.4K |
| Aug 20, 2026 | $12.65 | $12.67 | $12.47 | $12.56 | 49.95K |
| Aug 19, 2026 | $12.30 | $12.59 | $12.30 | $12.59 | 50.65K |
| Aug 18, 2026 | $12.60 | $12.77 | $12.48 | $12.64 | 284.84K |
| Aug 17, 2026 | $12.64 | $12.90 | $12.51 | $12.56 | 89.21K |
| Aug 14, 2026 | $12.19 | $12.27 | $12.08 | $12.20 | 13.09K |
| Aug 13, 2026 | $12.07 | $12.23 | $12.00 | $12.16 | 77.12K |
| Aug 12, 2026 | $12.36 | $12.40 | $12.21 | $12.25 | 34.29K |
| Aug 11, 2026 | $12.55 | $12.55 | $12.40 | $12.47 | 16.92K |
Latest HCM news
The latest Smart Investors Daily articles mentioning HCM.
Stock researchCompany · Overview
HCM research
Overview
Company profile and research snapshot.
Company profile
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $17.50
- Implied upside
- —
- Analysts
- 27
News briefing
Generated Sep 8, 2026, 9:11 PM
Why Is HCM Down Today?
HUTCHMED (China) Limited shares declined 1.49% today despite announcing a strategic partnership with GSK involving the licensing of oncology asset A830. The modest selloff suggests the market may be digesting the terms of the deal or taking profits, even as the company advances its pipeline through this notable collaboration.
Bottom line: While HUTCHMED's GSK partnership is strategically positive and validates its oncology pipeline, today's 1.49% decline suggests the market is taking a wait-and-see approach until more detailed financial terms are disclosed. Investors should monitor upcoming communications from the company regarding deal economics and any impact on full-year guidance, as the ultimate value of this partnership will depend heavily on milestone payments and royalty structures.
Yahoo · Sep 3, 2026
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr
Benzinga · Sep 3, 2026
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
Benzinga · Sep 3, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies (NASDAQ:BIAF)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
